Member Info for PirateFlag

Https://www.proactiveinvestors.com/companies/news/1024987?SNAPI

I have no.idea how this is going to play out but it would appear that Reverse Bio ( Age X's induced tissue regeneration - iTR for those familiar with the Age X pipeline) will be spun out but there is a lot of talk about other Juvenescence therapeutic companies moving into Serina Therapeutics (the Age X shell).

Whatever happens it looks like Juvenescence may finally be kicking into life!

Or maybe not...would be typical Mellon!

So the lack of comments has nothin to do with the lack of news then?

There is literally nothing to be said that hasn't been done to death a million times already. Nothing like a good conspiracy theory though, eh. Pmsl.

The_Wizards_Sleeve

I can't argue with that investingenius.

Ed has invested Seeds money into a company he co-founded while being very generously renumerated by Seed shareholders.

Not the first fime he has done it. The description shrewd operator doesn't really do him justice.

Https://www.bbc.co.uk/news/business-66438764

Whoosh!

Still not apologised to O'Donnel.

Poor form.

Never doubted it

AgeX went on a run today, up 32% and another 6% after hours.

NAV 7.54p

Thought so Mat. Not like doggo to get it wrong, most out of character I must say.

Would that be formal notice in the form of an RNS by any chance, Mat?

You sure about that doggo?

I trust you as you get everything else bang on 🤭

I doubt it I'm pretty sure a buy back has to be announced before it can take place.

Always did think inefor was a bit backwards ;

.

Yeah busy putting a go faster stripe on his race car.

Oncology drug developer Intensity Therapeutics (NASDAQ:INTS) has upsized its proposed initial public offering to $15M from $8M.

The biotech company said in a filing that it's now considering offering 3.25M shares priced between $4 and $5, which would raise around $15M if priced at the midpoint. Underwriters would be granted a 45-day option to buy up to 488K additional shares at the IPO price to cover any over-allotments.

In January, Intensity Therapeutics said it was looking to raise around $8M by offering 1.78M shares priced at $4.50 per share.

Intensity Therapeutics hopes to list its shares on Nasdaq under the symbol INTS. The Benchmark and Freedom Capital Markets are serving as joint bookrunners for the deal, according to its most recent filing.

Based in Connecticut, Intensity Therapeutics has developed drug technology that allows for cancer-fighting agents to be injected directly into tumors with a high absorption rate. The company's lead product, INT230-6, is currently in Phase 2 clinical testing for soft tissue sarcoma and breast cancer. It's also being tested in combination with Merck's (MRK) Keytruda and Bristol-Myers Squibb's (BMY) Yervoy.

Intensity Therapeutics first filed for an IPO in October 2021, seeking around $17M.

Dated 19th May 2023

It appears to be new news https://seekingalpha.com/news/3973606-intensity-therapeutics-upsizes-proposed-ipo-to-15m-from-8m

The only public company in the Juvenescence stable. Go Jim Mellon!